TY - JOUR
T1 - Biomarkers for Lung Cancer Screening and Detection
AU - Ostrin, Edwin J.
AU - Sidransky, David
AU - Spira, Avrum
AU - Hanash, Samir M.
N1 - Funding Information:
This work was supported by American Lung Association Lung Cancer Discovery Award 619882 (to E.J. Ostrin); NIH/NCI R01CA206027 and NIH/NCI R01CA208709 (to D. Sidransky); NIH/NCI 1U2CCA23323801S1, NIH/NCI 1U2CCA233238-01, and NIH/NCI 1U2CCA233238-01 (to A. Spira); and NIH/NCI 1U01CA194733-01A1, NIH/NCI 1U01CA213285-01A1, and NIH/NCI 1U19CA203654 (to S.M. Hanash).
Publisher Copyright:
© 2020 American Association for Cancer Research.
PY - 2020/12
Y1 - 2020/12
N2 - Lung cancer is the leading worldwide cause of cancer mortality, as it is often detected at an advanced stage. Since 2011, low-dose CT scan-based screening has promised a 20% reduction in lung cancer mortality. However, effectiveness of screening has been limited by eligibility only for a high-risk population of heavy smokers and a large number of false positives generated by CT. Biomarkers have tremendous potential to improve early detection of lung cancer by refining lung cancer risk, stratifying positive CT scans, and categorizing intermediate-risk pulmonary nodules. Three biomarker tests (Early CDT-Lung, Nodify XL2, Percepta) have undergone extensive validation and are available to the clinician. The authors discuss these tests, with their clinical applicability and limitations, current ongoing evaluation, and future directions for biomarkers in lung cancer screening and detection.
AB - Lung cancer is the leading worldwide cause of cancer mortality, as it is often detected at an advanced stage. Since 2011, low-dose CT scan-based screening has promised a 20% reduction in lung cancer mortality. However, effectiveness of screening has been limited by eligibility only for a high-risk population of heavy smokers and a large number of false positives generated by CT. Biomarkers have tremendous potential to improve early detection of lung cancer by refining lung cancer risk, stratifying positive CT scans, and categorizing intermediate-risk pulmonary nodules. Three biomarker tests (Early CDT-Lung, Nodify XL2, Percepta) have undergone extensive validation and are available to the clinician. The authors discuss these tests, with their clinical applicability and limitations, current ongoing evaluation, and future directions for biomarkers in lung cancer screening and detection.
UR - http://www.scopus.com/inward/record.url?scp=85101022175&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101022175&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-20-0865
DO - 10.1158/1055-9965.EPI-20-0865
M3 - Review article
C2 - 33093160
AN - SCOPUS:85101022175
SN - 1055-9965
VL - 29
SP - 2411
EP - 2415
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 12
ER -